Performance Comparison
Portfolio Performance Comparison
| Name | YTD Return | 1Yr AR | 3Yr AR | 5Yr AR | 10Yr AR | 15Yr AR | 20Yr AR | Common | Inception |
|---|---|---|---|---|---|---|---|---|---|
| CXRXF (ADVANZ PHARMA Corp. Limited) | NA | 353.72% | 336.59% | -6.44% | NA | NA | NA | … | … |
Data as of 06/10/2021, Common starting date is 02/13/2014
More Performance Analytics Comparison
| Name | Start Date | End Date |
|---|---|---|
| CXRXF (ADVANZ PHARMA Corp. Limited) | 02/13/2014 | 06/10/2021 |
| Last 1 Week | 1 Yr | 3 Yr | 5 Yr | 10 Yr | 15 Yr | 20 Yr | Common | Inception | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annualized Return (%) | -0.70 | 353.72 | 336.59 | -6.44 | NA | NA | NA | … | … | 286.85 | 51.44 | -84.71 | 2,798.02 | -69.01 | -94.81 | 0.84 | 246.36 |
| Sharpe Ratio | NA | 2.28 | 1.08 | -0.03 | NA | NA | NA | … | … | 11.61 | 0.31 | -0.97 | 5.41 | -0.64 | -0.85 | 0.01 | 6.74 |
| Standard Deviation(%) | NA | 155.22 | 321.82 | 259.49 | NA | NA | NA | … | … | 182.51 | 162.29 | 89.07 | 516.70 | 109.67 | 112.21 | 78.45 | 45.97 |
| Draw Down(%) | NA | 44.00 | 93.76 | 99.49 | NA | NA | NA | … | … | 14.99 | 82.93 | 86.09 | 85.66 | 86.93 | 95.56 | 72.53 | 16.06 |
| Yield(%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | … | … | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Data as of 06/10/2021, Common starting date is 02/13/2014
Performance Comparison Chart
Annualized Rolling Returns Comparison (Minimum)
| Ticker/Portfolio Name | 3 Year | 5 Year | 10 Year | 15 Year |
|---|---|---|---|---|
| CXRXF (ADVANZ PHARMA Corp. Limited) |
-86.96%
Aug 2015 – Aug 2018 |
-47.07%
Jul 2015 – Jul 2020 |
0.00%
NA |
0.00%
NA |
Annualized Rolling Returns Comparison (Maximum)
| Ticker/Portfolio Name | 3 Year | 5 Year | 10 Year | 15 Year |
|---|---|---|---|---|
| CXRXF (ADVANZ PHARMA Corp. Limited) |
312.61%
May 2018 – May 2021 |
3.14%
Mar 2014 – Mar 2019 |
0.00%
NA |
0.00%
NA |
Annualized Rolling Returns Comparison Chart
